Boehringer Ingelheim Achieves Phase III Survival Signal with Nerandomilast in IPF and PPF

Survival modeling from Boehringer Ingelheim's Phase III FIBRONEER™ program positions nerandomilast as a near-term NDA/MAA candidate, with manufacturing and regulatory teams likely already mapping the path from trial data to commercial-scale oral solid dosage production. Presented at ATS and EULAR 2026, the analyses predict nerandomilast 18 mg monotherapy could extend median survival to 9.1 years in IPF patients versus 3.7 years with no therapy, and to 7.2 years in PPF patients versus 3.9 years with no therapy.

The modeling applies Weibull distribution methodology to FIBRONEER™-IPF and FIBRONEER™-ILD trial data, projecting outcomes over a 30-year horizon under assumptions of consistent treatment effect and drug discontinuation rates observed in the trials. When nerandomilast 18 mg is added to background nintedanib, predicted median survival rises from 4.6 to 6.0 years in IPF and from 3.4 to 4.4 years in PPF. These are modeled estimates, not observed endpoints, and that distinction will carry weight in any regulatory submission package.

On the primary endpoint, nerandomilast met its mark in both trials, demonstrating statistically significant slowing of lung function decline measured by absolute change in FVC from baseline to week 52. The key secondary endpoint, time to first acute exacerbation, first respiratory hospitalization, or death, was not met in either individual trial. However, a pooled analysis across both FIBRONEER™ studies returned a nominally significant 59% reduction in risk of death for nerandomilast 18 mg monotherapy versus placebo, a result that will require careful framing under ICH E9(R1) estimand principles in any submission dossier.

For regulatory affairs leads, the combination of a met primary endpoint, a missed key secondary, and a pooled mortality signal creates a nuanced benefit-risk narrative. Agencies reviewing under 21 CFR Part 314 or EMA centralised procedure will scrutinise the statistical hierarchy and the robustness of the survival model assumptions. The tolerability profile, cited as a differentiator from existing antifibrotics, will also factor into the benefit-risk assessment, particularly given that sustained adherence underpins the long-term survival projections.

On the manufacturing side, nerandomilast is an oral preferential PDE4B inhibitor, a small-molecule modality that brings conventional GMP considerations around process validation, dissolution specification setting, and stability under ICH Q1 conditions. Scale-up from clinical to commercial batch sizes will require documented process characterisation aligned with ICH Q8 and Q11 expectations before any approval-enabling inspection.

The 59% pooled mortality reduction, if it survives regulatory scrutiny of the statistical methodology, could anchor the label claim that determines commercial positioning and long-term adherence strategies across both indications.

Source: Boehringer Ingelheim via GlobeNewswire, 18 June 2026. Data presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses.